D. Western Therapeutics Institute, Inc. (DWTI) announces that Japan Phase IIb clinical trials of anti-platelet agent K-134, which was discovered by DWTI and licensed to Kowa Company Ltd. (Kowa), has initiated by Kowa.

Japan Phase IIb clinical trials are conducted according to the Clinical Trials Information as per DWTI’s announcement “Notice regarding Japan Phase IIb clinical trials of anti-platelet agent K-134” on December 2, 2011.

Upon the initiation of the phase IIb clinical trials of K-134 in Japan, DWTI receives milestone payment as stated in a contract. DWTI will receive a total 112 million yen in Fiscal 2012, consisting of 2 consecutive milestone receipt of 37 million yen in the first quarter of Fiscal 2012 and 75 million yen in the third quarter of Fiscal 2012.

About K-134
K-134 is a novel selective PDE 3 inhibitor, discovered by DWTI, proved by The Drug Western method to bind with platelet collagen receptor, CD36 and actin-binding protein, Cofilin.
K-134 demonstrates potent efficacy on platelet aggregation inhibition. In addition, K-134 also exhibits potent anti-intimal hyperplasic activity in animal models.